Thin
Continuous flow synthesis, validated HPLC chromatography (>99.0% standard purity), and ultra-low endotoxin profiles for international pharmaceutical programs.
Thymosin Beta-4 (Tb4, CAS No: 77591-33-4) is a highly conserved 43-amino acid polypeptide (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH) with a molecular mass of 4963.5 Da. As the primary G-actin sequestering molecule across eukaryotic cells, Tb4 controls structural actin polymerization, cellular migration, neovascularization, and profound anti-inflammatory healing cascades.
| Analytical Attribute | Acceptance Criteria (Ph. Eur. / USP Reference) | Hangzhou Production Standard | Analytical Technique |
|---|---|---|---|
| Identity Verification | Conforms to monoisotopic molecular weight 4963.5 Da ± 1 Da | Confirmed (Single Peak, Zero Mismatch) | LC-MS / ESI-Q-TOF |
| Chromatographic Purity | ≥ 98.0% (AUC) | ≥ 99.2% Standard / ≥ 99.5% Ultra-Pure | Reversed-Phase HPLC (C18 / 214nm) |
| Specific Related Impurities | Total D-enantiomers < 1.5%; Deletion sequences < 0.5% | Max Individual Impurity ≤ 0.3% | UHPLC Gradient Separation |
| Peptide Content (Net) | ≥ 80.0% (Lyophilized base) | 84.5% - 88.0% | Elemental Nitrogen Analysis / Quantitative AAA |
| Residual Counter-Ion | Specified by dossier (Acetate ≤ 10.0%, TFA ≤ 0.25%) | Trifluoroacetate Exchange to Pure Acetate | Ion Chromatography (IC) |
| Residual Solvents | ICH Q3C Class 2 (DMF ≤ 880 ppm, MeCN ≤ 410 ppm) | DMF < 50 ppm, DCM Not Detected | Headspace GC-MS |
Navigating the commercial supply of complex long-chain peptides requires transitioning beyond laboratory-scale manual synthesis. Hangzhou Thinheal Pharma-Tech combines 20 years of technical management with domestic upstream chemical integration to lower raw material cost barriers while maintaining stringent cGMP compliance.
Utilizing high-throughput microwave-assisted SPPS and hybrid liquid-phase fragment condensation, our facility achieves reliable sequence elongation for Tb4's 43-residue backbone, drastically eliminating deletion peptide side reactions.
By producing protected Fmoc-amino acids and specialized coupling reagents (HATU, PyBOP, HOBt) internally within the Zhejiang-Jiangsu industrial corridor, we protect enterprise clients from global price volatility and raw material delays.
Our dynamic axial compression (DAC) column arrays handle kilogram-scale single injections, coupled with non-destructive lyophilization technology that converts toxic trifluoroacetate (TFA) salts to pharmaceutical-grade biocompatible acetate salts.
Procuring peptide APIs requires absolute confidence in audit-readiness and regional regulatory compatibility. Hangzhou Thinheal delivers full lifecycle compliance, facilitating IND/NDA filings across North America (US FDA), the European Union (EMA), CIS regions, and the Asia-Pacific zone.
We provide full Common Technical Document (CTD) formats covering synthetic route proofs, critical process parameter (CPP) validation, complete impurity profiling, and residual solvent clearance pathways.
Tb4 is shipped under validated temperature-controlled conditions (-20°C with real-time IoT temperature logging). We execute pre-cleared DDP/DAP shipments directly to research labs, CDMOs, and sterile fill-finish operations worldwide.
Real-time and accelerated stability programs (25°C/60% RH, 40°C/75% RH, and long-term -20°C storage) substantiate extended shelf life and reconstitution parameters for sterile lyophilized formulation products.
Peptide pricing is governed by three primary pillars: scale, purification yield, and salt exchange validation. Below is an indicative industry benchmark designed to assist procurement directors in Total Cost of Ownership (TCO) evaluation.
| Order Volume Tier | Target Purity Grade | Counter-Ion Type | Lead Time | Price Guidance (USD / Gram) | Quality Documentation Provided |
|---|---|---|---|---|---|
| Research Tier (1g - 10g) | ≥ 98.0% HPLC | TFA Salt | In Stock (24h Dispatch) | $140 - $190 / g | CoA, HPLC, MS Spectrum |
| Development Tier (50g - 250g) | ≥ 98.5% HPLC | TFA or Standard Acetate | 1 - 2 Weeks | $75 - $110 / g | CoA, HPLC, MS, Residual Solvents |
| Pilot Campaign (500g - 1,000g) | ≥ 99.0% HPLC | Pharmaceutical Acetate | 3 - 4 Weeks | $45 - $65 / g | Full Batch Record, Heavy Metals, Endotoxin |
| Commercial Batch (5kg - 25kg+) | ≥ 99.2%+ Custom Spec | Ultra-Pure Acetate / Salt-Free | Scheduled Supply Agreement | Contact Regional Desk | Complete CTD Module 3, cGMP Site Audit Access |
Due to its broad actin-cytoskeleton modulation and vascular regenerative attributes, Thymosin Beta-4 is deployed across specialized drug delivery platforms, medical aesthetic formulations, and acute critical care therapies.
Tb4 eye drops are studied extensively for Neurotrophic Keratopathy and Severe Dry Eye Syndrome (DED), promoting prompt re-epithelialization of the corneal epithelium while suppressing TGF-β driven scarring.
Clinical investigations demonstrate Tb4's potential in activating dormant cardiac progenitor cells, improving myocyte survival, and reducing scar formation following acute myocardial infarction (AMI).
Accelerating dermal fibroblast migration and collagen organization, Tb4 is integrated into advanced hydrogels and bio-dressings for diabetic foot ulcers, chronic venous ulcers, and post-surgical scar mitigation.
The global peptide therapeutics sector is witnessing rapid structural shifts driven by GLP-1 commercial demand and regenerative peptide approvals. Key macro trajectories shaping modern procurement include:
Regulatory mandates are compelling producers to eliminate toxic dipolar aprotic solvents such as DMF and NMP. Hangzhou Thinheal implements bio-based alternative solvents (Cyrene, 2-MeTHF) and automated solvent recovery cycles to achieve high ESG alignment.
Machine learning models predict aggregation dynamics in difficult sequences during coupling reactions, allowing real-time UV-monitored reagent addition and preventing deletion impurities before cleavage steps occur.
Western biotechs are maintaining blended supply frameworks—coupling domestic western fill-finish operations with China-based multi-ton API core manufacturers to safeguard pipeline economics against margin compression.
Addressing essential technical, regulatory, and quality control inquiries raised by sourcing managers, analytical chemists, and formulation scientists.
Discover our broader catalog of peptide active ingredients, backed by multi-ton manufacturing infrastructure and rigorous analytical documentation.
